Biotech Investors Are Waiting For The Wrong Milestone In AI Drug Discovery

The article argues that biotech investors focus excessively on AI's ability to directly discover new drug molecules, overlooking significant value in AI-driven enhancements across the drug development process, including target identification and clinical trial acceleration.

This Wire brief sits within Fusion42's coverage of Biotech.